{"id":"W2603044866","doi":"10.1200/jco.2017.35.4_suppl.tps213","title":"Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Medicine; Nivolumab; Oxaliplatin; Internal medicine; Ipilimumab; Cancer; Oncology; Phases of clinical research; Chemotherapy; Gastroenterology; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001694991,0.001606915,0.001842188,0.0004935796,0.0004451811,0.001390153,0.001042121,0.001704291,0.006968328],"category_scores_gemma":[0.001285754,0.0007300284,0.001545385,0.0004254265,0.0009923928,0.0009923271,0.0004217148,0.00326409,0.001318745],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001066083,"about_ca_system_score_gemma":0.001443809,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001368139,"about_ca_topic_score_gemma":0.003493878,"domain_scores_codex":[0.9996561,0.0001859196,0.00001349588,0.00006023602,0.00002477269,0.00005945583],"domain_scores_gemma":[0.9992394,0.0001687559,0.0001669556,0.00004706443,0.00003850721,0.0003392366],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9543042,0.01762557,0.0008948794,0.0005032598,0.0007307925,0.00005613746,0.000077727,0.0007007533,0.007137456,0.0001535015,0.001691354,0.01612435],"study_design_scores_gemma":[0.91043,0.08554593,0.001625164,0.00001972835,0.0003180019,0.00003548733,0.00001671032,0.0005796022,0.0004990473,0.00009808632,0.0008178621,0.00001441882],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859849,0.00263201,0.0007936233,0.0006957928,0.0005280876,0.004931125,0.00173041,0.0002124524,0.00249163],"genre_scores_gemma":[0.9830862,0.00196569,0.001711911,0.001574824,0.0004007223,0.004849944,0.002216861,0.00005623454,0.004137625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006968328,"threshold_uncertainty_score":0.02331138,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.179962240909258,"score_gpt":0.4946128004632462,"score_spread":0.3146505595539882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}